INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 80 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $26,306 | +31.6% | 124,968 | 0.0% | 0.00% | – |
| Q1 2023 | $19,995 | -71.2% | 124,968 | 0.0% | 0.00% | – |
| Q4 2022 | $69,357 | -53.5% | 124,968 | 0.0% | 0.00% | – |
| Q3 2022 | $149,000 | +204.1% | 124,968 | +62.3% | 0.00% | – |
| Q2 2022 | $49,000 | -61.4% | 76,991 | -31.1% | 0.00% | – |
| Q1 2022 | $127,000 | -49.6% | 111,783 | 0.0% | 0.00% | – |
| Q4 2021 | $252,000 | -34.2% | 111,783 | -0.3% | 0.00% | – |
| Q3 2021 | $383,000 | -93.3% | 112,100 | -74.8% | 0.00% | -100.0% |
| Q2 2014 | $5,676,000 | +7.2% | 445,500 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $5,297,000 | -11.9% | 445,500 | +2.4% | 0.00% | 0.0% |
| Q4 2013 | $6,010,000 | -9.7% | 435,200 | +14.0% | 0.00% | -25.0% |
| Q3 2013 | $6,659,000 | +41.3% | 381,600 | +31.5% | 0.00% | +33.3% |
| Q2 2013 | $4,714,000 | – | 290,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |